Simple Intensive Care Studies I (SICS-I)

NCT ID: NCT02912624

Last Updated: 2018-04-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1090 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-03-27

Study Completion Date

2017-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Circulatory shock is a condition of generalized inadequate blood flow through the body, leading to insufficient tissue perfusion and inadequate delivery of oxygen and other nutrients, to the extent that tissues are damaged. Four basic mechanisms of circulatory failure are distinguished, caused by a scale of underlying illnesses: distributive, hypovolemic, obstructive and cardiogenic shock. The last three types are characterized by a low cardiac output and hypovolemia. Distributive shock is characterized by peripheral circulation failure, with a low systemic vascular resistance, a disturbed microcirculation and a high cardiac output. Frequently, these forms overlap.

Shock is a common problem in the intensive care unit (ICU) as it affects about one third of the patients. Septic shock appears to be the most common type, followed by cardiogenic and hypovolemic shock. The diagnosis of shock is based on clinical examination with use of well-known circulatory parameters such as blood pressure and heart rate; biochemical parameters such as lactate and direct (semi-)invasive measurement of cardiac output and other variables.

Since cardiac output is an important determinant of oxygen delivery, many different methods of measuring cardiac output have been suggested. These methods range from non-invasive to invasive measurements with central lining. The most invasive method, the pulmonary artery catheter (PAC) has long been considered the optimal form of monitoring cardiac output by using thermodilution. However, this technique is associated with adverse events, such as bleeding, and there is no clear evidence of improved outcome. Therefore, numerous other techniques have been proposed, ranging from systems that use the dilution technique but only require central venous and peripheral artery lines; to less invasive tools that estimate cardiac output based on the arterial pressure waveform; and to non-invasive echocardiography.

Despite technical advances, much remains unknown about the value of conventionally used hemodynamic parameters for estimating cardiac output. A distinction between macro- and microcirculatory parameters can be made. Commonly used macro-circulatory parameters are heart rate, systolic and diastolic blood pressure, mean arterial pressure and central venous pressure. Lactate is used as a proxy for microcirculatory status. Over the years several other measurements have been suggested to improve insight in the hemodynamics of a certain patient or a group of patients. Skin temperature, capillary refill, mottling score and urinary output are used for hemodynamic assessment of the peripheral circulation and tissue perfusion. Most of these parameters have not been evaluated in a large prospective study and especially a combination of all these parameters has not directly been correlated to cardiac output.

More knowledge on the predictive value of all hemodynamic parameters in estimating cardiac output could assist physicians in earlier detection of impaired hemodynamics without the need for invasive or advanced methods. In this study the investigators aim to evaluate all hemodynamic parameters in a large unselected population of critically ill patients and to correlate them to cardiac output.

Purpose:

The purpose of this study is to create an infrastructure for a registry flexible to incorporate temporarily added specific research questions on the outcome of critically ill patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Registry procedures:

Eligible patients will be included within 24 hours after their arrival on the Intensive Care Unit. After inclusion all study parameters will be obtained once through physical examination combined with transthoracic echocardiography. Mortality will be assessed at 90 days after admission. In addition, mortality follow-up will be cut-off at 7 and 30 days after admission.

Monitoring:

Monitoring will be performed by independent researchers of the department of anaesthesiology of the UMCG. Audits are planned to take place once a year.

Quality assurance plan:

Recruitment:

Inclusion of patients and measurements of variables (both conventional hemodynamic variables and cardiac output) will be performed by the study coordinator or a co-researcher under supervision and responsibility of the principle investigator. Informed consent will be obtained.

Source data verification:

At inclusion all conventional hemodynamic variables are derived by physical examination and recording data from the basic hemodynamic monitoring (Philips ImageVue monitor with tracing of heart rate, electrocardiogram (ECG), SpO2, arterial pressure from arterial line pressure measurement and/or from non-invasively blood pressure monitoring). In addition, a transthoracic echocardiography (TTE) will be performed to non-invasively determine the cardiac output by using the diameter of the aortic annulus, the velocity time integral (VTI) of the Doppler flow and the heart rate. All variables are predefined (see data dictionary) to standardize all measurements by student researchers.

For the performance of the TTE the student researchers will be trained to visualize the parasternal 2 chamber view, apical 4 and 5 chamber view according to the international standards (ACC/ESC) and to measure the left ventricular outflow tract VTI and the diameter of the aortic annulus. The training was given by an experienced cardiologist-intensivist. All measurements were validated by an echocardiography technician (core laboratory) who was blinded for all other measurement outcomes. General patient characteristics and laboratory measurements were recorded from electronic patient charts and the APACHE II and IV, Simplified Acute Physiology Score II (SAPS) scores are extracted from our local National Intensive Care Evaluation database. Follow-up of all-cause mortality is acquired using the municipal personal records database.

Standard Operation Procedures

Data collection:

Within 24 hours of ICU admission, all hemodynamic variables will be obtained through a onetime physical examination combined with transthoracic echocardiography. Other variables (i.e. lab values) will be obtained from the electronic patient charts at a later moment. The rationale and specific details of measuring each variable are described extensively below.

Systemic circulatory variables:

* Cardiac output (CO): it will be measured by transthoracic echocardiography, performed by different trained researchers. Both cardiac output and cardiac index (i.e. cardiac output corrected for body surface area) will be calculated.
* Stroke volume (SV): this will be automatically calculated by dividing cardiac output by heart rate, both measured by transthoracic echocardiography.
* Heart rate (HR): it will be recorded from the bedside electrocardiographic monitor. In case of an irregular rhythm (i.e. atrial fibrillation) the investigators will use the mean heart rate over a minute. Apart from heart rate the presence of atrial fibrillation will be recorded.
* Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP): these will be obtained by intravascular measurement using an arterial line, which is part of usual care. To allow for comparison, these variables will also be measured using a sphygmomanometer. In the latter case, mean arterial pressure will be calculated using the following formula: MAP = (SBP + 2\*DBP)/3
* Central venous pressure (CVP): this will be recorded in case a central venous line is present in the internal jugular or subclavian vene.

Micro- and peripheral circulatory variables:

* Capillary refill time (CRT): this will be measured after 15 seconds of exerting firm pressure preferably on the distal phalanx of the index finger and on the central part of the knee. The original upper limit of a normal CRT was considered to be 2 seconds by Champions' Trauma score. However Schriger and Baraff examined CRT in a healthy population and discovered it to be age and temperature dependent, with an upper limit for healthy older adults of 4.5 seconds. In a recent study Ait-Oufella et al found that an index CRT upper limit of 2.4 seconds is predictive of 14 day mortality in septic shock patients. The investigators will therefore both use a cut-off value of 4,5 seconds and a continuous measure of CRT.
* Skin temperature (Tskin): this will be measured subjectively and objectively. The subjective measure will be conducted by palpating the patient's extremities. A distinction between either 'warm' or 'cold' will be made using the dorsal surface of the hands of the examiner. Patients will be considered to have 'cold' skin extremities if all examined extremities are considered cool, or if only the lower extremities are cool despite warm upper extremities.

To objectify the skin temperature, the use of a central-to-peripheral and peripheral-to-ambient temperature difference (respectively dTc-p and dTp-a) or the forearm-to-finger skin-temperature gradient (Tskin-diff) have been proposed in literature. The investigators will make use of the central-to-peripheral measurements:

* Central-to-peripheral temperature difference (dTc-p): to measure this difference the investigators will compare bladder temperature, as measured by a bladder thermistor catheter, with foot temperature, measured by a skin probe (DeRoyal Skin Temperature Sensor product nr 81-010400EU) on either the left or the right big toe. The investigators will use bladder temperature as a surrogate for central temperature, and toe temperature as a peripheral measure. In literature a temperature difference of either 5°C or 7 °C is generally used as an upper limit. The investigators will therefore regard values higher than 7°C as abnormal.
* The mottling score: this score was described by Ait-Oufella et al in 2011. Mottling is the patchy discoloration of the skin caused by microcirculatory dysfunction. It usually involves the area around the knee. The Mottling score ranges from 0 -5, depending on the extensiveness of the mottled area. A score of 0-1 is regarded mild, 2-3 moderate and 4-5 severe.
* Urine output (ml/kg/h): this is also measured as part of regular care. The investigators will use both the urine output over the hour before examination and the mean urine output per hour, calculated using the six hours prior to the physical examination. If these data are unavailable, the mean urine output of the previous hour(s) will be calculated depending on the available data. In patients with pre-existing renal failure the urinary output will not be used.

Other variables:

* Respiratory rate: this will be recorded of the bedside electrocardiographic monitor. If a patient is on mechanical ventilation, see below.
* AVPU scale: this can be used to obtain a quick impression of a patients state of consciousness and consists of the options: 'Alert', 'responsive to Voice', 'responsive to Pain' and 'Unresponsive.' It is often applied in the emergency room and the general wards as part of the 'MEWS' (Modified Early Warning Score). The investigators will score the AVPU scale as a separate item.
* Cardiac murmurs: the investigators will auscultate the heart for the presence of a murmur. The potential cause of a cardiac murmur ranges from completely innocent to advanced valvular disease, each with its own distinctive characteristics. For study purposes, the investigators will score this item as: present or absent.
* Crepitations: the investigators will auscultate the lungs for crepitations, or crackles. In general a distinction between in- or expiratory and fine or coarse crepitations is made. Crepitations can be a symptom of several diseases, ranging from pneumonia and pulmonary edema to interstitial lung fibrosis. For study purposes, the investigators will only make a distinction in: present or absent.
* Serum lactate, creatinine and hemoglobin: these are determined as part of regular care. For study purposes the investigators will use the value closest to our examination. Other biochemical values will also be recorded.
* Mechanical ventilation: data on the presence and type of mechanical ventilation will be gathered, as well as basic information on respiratory conditions (i.e. PEEP and respiratory rate). Note: in case of mechanical ventilation the value 'respiratory rate' will be filled in twice in the CRF. If both values are the same, it will be assumed that the patient breathes at a machine-set respiratory rate. If they differ, spontaneous breathing will be assumed.
* Inotrope-, vasopressor and sedative use: any inotrope or vasopressin requirement, type, dose and speed will be recorded.
* Estimations of pump function and peripheral circulation: an estimation will be made, either by a member of the treating team, or by the researcher.

After the physical examination has been performed, information on the following general characteristics will be extracted from patient files: demographic data, diagnoses and severity of illness as evaluated by the APACHE II and IV scores, Simplified Acute Physiology Score II (SAPS) and the Sequential Organ Failure Assessment (SOFA). Furthermore the investigators will collect EMV scores, lab values (details are described above), urine output (details are described above), routine admission ECG's and routine admission thorax photo's. After 90 days the investigators will assess the patient files again to gather information on total ICU stay in days and 7-, 28- and 90-day mortality.

Data management:

Data will be recorded using OpenClinica and transferred for analysis. After transfer from OpenClinica, all data will be managed in a database created using Stata version 14.1 (StataCorp, College Station, TX) All study subjects will receive a study subject ID, compiled of the study name and their inclusion number. This study subject ID will be used in both OpenClinica and Stata. Only a researcher with 'study director' account properties in OpenClinica will be able to link study subject ID to patient number. Images will be saved anonymously and will be coded in a systematic fashion, using the study subject ID, session number, and image contents.

Sample size assessment:

There are no previous studies with data on including a combination of all available hemodynamic variables into one model estimating cardiac output and mortality. This makes it difficult to calculate sample size. The investigators will therefore make an estimation based on the number of ICU admissions per year. Each year 3000 patients are admitted to one of four ICU units. Approximately 1500 of these admissions are unplanned emergency admissions. The investigators estimate that half of these unplanned admissions fulfill the inclusion criteria. This leaves 750 patients eligible for inclusion. However, the investigators assume that they will not be able to include all eligible patients for logistic and practical reasons. Therefore the investigators aim to include 400 patients per year. With emergency admission critical care mortality approaching 25% this will enable us to include at least ten variables in the final model for predicting mortality (acknowledging that at least 10 events are necessary for each variable included in the final model). We will describe the power and detectable difference in a detailed statistical analysis plan (SAP).

Plan for missing data:

Primary analyses will be performed with imputation for missing data using multiple imputations. Robustness of conclusions will be checked by secondary sensitivity analyses only including available data. We will describe additional information in a detailed statistical analysis plan.

Statistical analysis plan:

The investigators will use the general characteristics to create a baseline table. Statistical analyses will be performed using the Stata (StataCorp, College Station, TX). Data will be presented as means with standard deviation if normally distributed or as medians with ranges in case of skewed data.

Univariate analyses will be conducted and all variables with p\<0.1 will be included in the multivariate models. Multivariate analyses will be conducted using a stepwise model. Cardiac output will be modeled using linear regression and mortality will be modeled using logistic regression. All analyses will be adjusted for age and gender; other general characteristics will not be added to the model standardly. All analyses will be tested two-sided and p-values of less than 0.015 will be considered statistical significant. Multiplicity issues are described in our detailed SAP.

If sample size permits, the investigators will conduct an analysis in different subpopulations. Examples of subpopulations that may be eligible for further analysis are those with different types of shock (distributive, obstructive, hypovolemic, cardiogenic), CVVH, heart failure by any cause, myocardial infarction, atrial fibrillation or surgery versus no-surgery patient groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critical Illness Acute Disease Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Emergency admission
* Expected stay \> 24 hours

Exclusion Criteria

* Age \< 18 years
* Planned admission (either after surgery or for other reasons)
* Withdrawn or unable to obtain informed consent
* Continuous resuscitation efforts or mechanical circulatory support
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Copenhagen Trial Unit, Center for Clinical Intervention Research

OTHER

Sponsor Role collaborator

University Medical Center Groningen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

I.C.C. van der Horst

Associate professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Iwan CC van der Horst, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Groningen, University Medical Center Groningen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Medical Center Groningen

Groningen, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Hiemstra B, Eck RJ, Koster G, Wetterslev J, Perner A, Pettila V, Snieder H, Hummel YM, Wiersema R, de Smet AMGA, Keus F, van der Horst ICC; SICS Study Group. Clinical examination, critical care ultrasonography and outcomes in the critically ill: cohort profile of the Simple Intensive Care Studies-I. BMJ Open. 2017 Sep 27;7(9):e017170. doi: 10.1136/bmjopen-2017-017170.

Reference Type BACKGROUND
PMID: 28963297 (View on PubMed)

Cox EGM, Wiersema R, Eck RJ, Kaufmann T, Granholm A, Vaara ST, Moller MH, van Bussel BCT, Snieder H, Pleijhuis RG, van der Horst ICC, Keus F. External Validation of Mortality Prediction Models for Critical Illness Reveals Preserved Discrimination but Poor Calibration. Crit Care Med. 2023 Jan 1;51(1):80-90. doi: 10.1097/CCM.0000000000005712. Epub 2022 Nov 15.

Reference Type DERIVED
PMID: 36378565 (View on PubMed)

Cox EGM, Koster G, Baron A, Kaufmann T, Eck RJ, Veenstra TC, Hiemstra B, Wong A, Kwee TC, Tulleken JE, Keus F, Wiersema R, van der Horst ICC; SICS Study Group. Should the ultrasound probe replace your stethoscope? A SICS-I sub-study comparing lung ultrasound and pulmonary auscultation in the critically ill. Crit Care. 2020 Jan 13;24(1):14. doi: 10.1186/s13054-019-2719-8.

Reference Type DERIVED
PMID: 31931844 (View on PubMed)

Koster G, Kaufmann T, Hiemstra B, Wiersema R, Vos ME, Dijkhuizen D, Wong A, Scheeren TWL, Hummel YM, Keus F, van der Horst ICC. Feasibility of cardiac output measurements in critically ill patients by medical students. Ultrasound J. 2020 Jan 8;12(1):1. doi: 10.1186/s13089-020-0152-5.

Reference Type DERIVED
PMID: 31912438 (View on PubMed)

Kaufmann T, Castela Forte J, Hiemstra B, Wiering MA, Grzegorczyk M, Epema AH, van der Horst ICC; SICS Study Group. A Bayesian Network Analysis of the Diagnostic Process and Its Accuracy to Determine How Clinicians Estimate Cardiac Function in Critically Ill Patients: Prospective Observational Cohort Study. JMIR Med Inform. 2019 Oct 30;7(4):e15358. doi: 10.2196/15358.

Reference Type DERIVED
PMID: 31670697 (View on PubMed)

Kaufmann T, Clement RP, Hiemstra B, Vos JJ, Scheeren TWL, Keus F, van der Horst ICC; SICS Study Group. Disagreement in cardiac output measurements between fourth-generation FloTrac and critical care ultrasonography in patients with circulatory shock: a prospective observational study. J Intensive Care. 2019 Apr 11;7:21. doi: 10.1186/s40560-019-0373-5. eCollection 2019.

Reference Type DERIVED
PMID: 31011425 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201500144

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.